Glenmark Pharmaceuticals, A Research-Led, Integrated Global Pharmaceutical Company, Has Launched Antiviral Drug Favipiravir (Brand Name Fabiflu) For The Treatment Of Mild To Moderate Covid-19 Patients.The Drug Will Be Available As A Prescription-Based Medication For Rs. 103 A Tablet, With Recommended Dose Being 1800 Mg Twice Daily On Day 1, Followed By 800 Mg Twice Daily Up To Day 14.Glenmark Has Received Manufacturing And Marketing Approval From India&Rsquo;S Drug Regulator, Making Fabiflu The First Oral Favipiravir-Approved Medication In India For The Treatment Of Covid-19.Favipiravir Is Backed By Strong Clinical Evidence Showing Encouraging Results In Patients With Mild To Moderate Covid-19. The Antiviral Offers Broad Spectrum Rna Virus Coverage With Clinical Improvement Noted Across Age Groups 20 To ≫90 Years.Favipiravir Can Be Used In Covid-19 Patients With Co-Morbid Conditions Such As Diabetes And Heart Disease With Mild To Moderate Covid 19 Symptoms. Favipiravir Has Shown Clinical Improvement Of Up To 88% In Covid-19 Mild To Moderate Covid 19 Cases.Glenn Saldanha, Chairman And Managing Director Of Glenmark Pharmaceuticals Ltd., Said, &Ldquo;This Approval Comes At A Time When Cases In India Are Spiralling Like Never Before, Putting A Tremendous Pressure On Our Healthcare System. We Hope The Availability Of An Effective Treatment Such As Fabiflu Will Considerably Help Assuage This Pressure, And Offer Patients In India A Much Needed And Timely Therapy Option.&Rdquo;He Added, &Ldquo;Fabiflu Has Demonstrated An Encouraging Response In Mild To Moderate Covid-19 Patients During Clinical Trials. Moreover, It Is Orally Administered, And So It Serves As A More Convenient Treatment Option Over Other Intravenously Administered Medications. Glenmark Will Work Closely With The Government And Medical Community To Make Fabiflu Quickly Accessible To Patients Across The Country.&Rdquo;Favipiravir Is Approved In Japan Since 2014 For The Treatment Of Novel Or Re-Emerging Influenza Virus Infections. It Has A Unique Mechanism Of Action: It Is Converted Into An Active Phosphoribosylated Form (Favipiravir-Rtp) In Cells And Recognized As A Substrate By Viral Rna Polymerase, Thereby Inhibiting Rna Polymerase Activity."
